Celltrion CCO On The Big US Build-Up, Direct Sales Model

 
• By Anju Ghangurde

Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.

Celltrion Readies Big US Push • Source: Shutterstock

Celltrion’s biosimilar bevacizumab has just made its US debut and the South Korean company hopes to find a “sweet spot” to make an impact and take on formidable competition.

Leading the charge is Celltrion’s new US chief commercial officer and seasoned executive, Thomas Nusbickel, who is confident his ‘experienced’ team will be able to deliver results for Vegzelma (bevacizumab-adcd),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip